Paul Tudor Jones's VNDA Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 102,255 shares of Vanda Pharmaceuticals Inc. (VNDA) worth $706,582, representing 0.00% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 43 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in VNDA, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 109,813 shares. Largest reduction occurred in Q2 2024, reducing 139,040 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Vanda Pharmaceuticals (VNDA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vanda Pharmaceuticals (VNDA) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +13,667 | Add 15.43% | 102,255 | $6.91 |
| Q4 2025 | -40,048 | Reduce 31.13% | 88,588 | $8.82 |
| Q3 2025 | -8,653 | Reduce 6.30% | 128,636 | $4.99 |
| Q2 2025 | +2,858 | Add 2.13% | 137,289 | $4.72 |
| Q1 2025 | +109,813 | Add 446.07% | 134,431 | $4.59 |
| Q4 2024 | +9,180 | Add 59.46% | 24,618 | $4.79 |
| Q3 2024 | +15,438 | New Buy | 15,438 | $4.69 |
| Q2 2024 | -139,040 | Sold Out | 0 | $0.00 |
| Q1 2024 | +102,628 | Add 281.85% | 139,040 | $4.11 |
| Q4 2023 | +36,412 | New Buy | 36,412 | $4.22 |
| Q1 2023 | -10,740 | Sold Out | 0 | $0.00 |
| Q4 2022 | +10,740 | New Buy | 10,740 | $0.01 |
| Q3 2022 | -66,114 | Sold Out | 0 | $0.00 |
| Q2 2022 | -32,242 | Reduce 32.78% | 66,114 | $10.91 |
| Q1 2022 | +30,846 | Add 45.69% | 98,356 | $11.31 |
| Q4 2021 | +49,660 | Add 278.21% | 67,510 | $15.69 |
| Q3 2021 | -17,570 | Reduce 49.60% | 17,850 | $17.14 |
| Q2 2021 | -19,833 | Reduce 35.89% | 35,420 | $21.51 |
| Q1 2021 | +34,498 | Add 166.22% | 55,253 | $15.02 |
| Q4 2020 | -12,024 | Reduce 36.68% | 20,755 | $13.15 |
| Q3 2020 | +6,780 | Add 26.08% | 32,779 | $9.67 |
| Q2 2020 | -83,611 | Reduce 76.28% | 25,999 | $11.42 |
| Q1 2020 | +20,812 | Add 23.44% | 109,610 | $10.36 |
| Q4 2019 | -44,619 | Reduce 33.44% | 88,798 | $16.41 |
| Q3 2019 | +476 | Add 0.36% | 133,417 | $13.28 |
| Q2 2019 | +36,861 | Add 38.36% | 132,941 | $14.09 |
| Q1 2019 | +37,348 | Add 63.59% | 96,080 | $18.40 |
| Q4 2018 | +33,605 | Add 133.74% | 58,732 | $26.14 |
| Q3 2018 | -65,564 | Reduce 72.29% | 25,127 | $22.96 |
| Q2 2018 | +20,305 | Add 28.85% | 90,691 | $19.05 |
| Q1 2018 | +51,214 | Add 267.13% | 70,386 | $16.85 |
| Q4 2017 | +4,582 | Add 31.41% | 19,172 | $15.18 |
| Q3 2017 | -15,221 | Reduce 51.06% | 14,590 | $17.89 |
| Q2 2017 | -13,847 | Reduce 31.72% | 29,811 | $16.30 |
| Q1 2017 | -6,889 | Reduce 13.63% | 43,658 | $14.00 |
| Q4 2016 | +1,594 | Add 3.26% | 50,547 | $15.95 |
| Q3 2016 | +36,234 | Add 284.88% | 48,953 | $16.65 |
| Q2 2016 | +12,719 | New Buy | 12,719 | $11.16 |
| Q1 2016 | -43,204 | Sold Out | 0 | $0.00 |
| Q4 2015 | +2,428 | Add 5.95% | 43,204 | $9.30 |
| Q3 2015 | +19,582 | Add 92.39% | 40,776 | $11.28 |
| Q2 2015 | -3,806 | Reduce 15.22% | 21,194 | $12.69 |
| Q1 2015 | +25,000 | New Buy | 25,000 | $9.28 |
Paul Tudor Jones's Vanda Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Vanda Pharmaceuticals Inc. (VNDA) in Q1 2015, acquiring 25,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Vanda Pharmaceuticals Inc. (VNDA) for 43 quarters since Q1 2015.
Paul Tudor Jones's largest addition to Vanda Pharmaceuticals Inc. (VNDA) was in Q1 2025, adding 134,431 shares worth $617,038.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 102,255 shares of Vanda Pharmaceuticals Inc. (VNDA), valued at approximately $706,582.
As of the Q1 2026 filing, Vanda Pharmaceuticals Inc. (VNDA) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Vanda Pharmaceuticals Inc. (VNDA) was 139,040 shares, as reported at the end of Q1 2024.